• Sentiment among UK CFOs has risen for the second consecutive quarter, with optimism running well above average levels;
• Inflation and high interest rates have dropped down the CFO risk list;1
• Corporate risk appetite has risen to an 18-month high but remains subdued relative to its long-term average;
• 63% of CFOs anticipate higher investment in new technology;
• CFOs believe geopolitical factors pose the greatest external risk to their own businesses over the next 12 months.
News
CAMBRIDGE, UK & BOSTON, US – JANUARY 2, 2024 – Apollo Therapeutics (“Apollo” or “the Company”), a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.
ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION
Cambridge, UK, 8 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
- Helix Geospace, a leading developer of next-generation antennas and systems, has leased laboratory space at Abingdon Science Park: one of the UK’s critical science and technology hubs.
- Owned and developed by Kadans Science Partner, the brand new, laboratory accommodation is designed to meet the demands of innovative occupiers.
Happy new year to our fantastic members, partners, sponsors and collaborators.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT, COMMERCIAL AND GENERAL MANAGER OF TETRIS PHARMA LTD
Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pharma Ltd ("Tetris Pharma”), effective Monday 15 January 2024.
James Sheppard, Managing Director (UK&I) at Kadans
Maintaining the pace of innovation required during the pandemic was never going to be easy. From the boom in demand in 2020, to the inflationary and market pressures in 2023, it has been a turbulent few years for the life sciences industry.
VANCOUVER, Wash., US and OXFORD, UK, December 20, 2023 — Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.
New Scientist, in association with SRG, is conducting a global salary, employment and industry survey (Life Sciences, Clinical & Engineering) to provide you with the latest insights into your salary. The results of this survey benchmarking salary will be published on the SRG website. Be part of the conversation and participate today!